Gastric cancer (GC) is the second leading cause of cancer-related death worldwide, although its incidence in many Western countries declined during the last decade. Chemotherapy is widely used to treat GC, and a number of randomized studies have recently demonstrated that systemic treatment can improve overall survival (OS) or quality of life. However, expected survival for the advanced disease is generally poor (less than 1 year). A number of newer chemotherapeutic compounds have been studied intensively. These include taxanes, topoisomerase I inhibitors and oral fluoropyrimidines, as well as new biological agents aiming to inhibit or modulate different targets of signaltransduction pathways or angiogenesis. However, no active second-line therapy has demonstrated definitive clinical benefit in patients with advanced GC, and in some patients therapy results solely in severe, unpredictable toxicity without any tumor response. It is therefore crucial to individualize GC chemotherapy to allow the discernment of patients in whom a particular therapy will exert a real benefit.
Pharmacogenetics has emerged as a promising new tool for better therapy design. However, despite encouraging prospects, data reported so far are conflicting and need critical consideration before translation to the treatment of GC. In this review, we discuss recent data concerning possible roles for genetic polymorphisms in GC treatment.
5-fluorouracil (5-FU) is the basis for several combinatory regimens or single-agent chemotherapy in GC. Two enzymes are known to affect therapy outcome: thymidilate synthase (TYMS; the major intracellular 5-FU target) and dihydropyrimidine dehydrogenase (DPYD; involved in 5-FU catabolic inactivation). Many studies indicate that low levels of DPYD or TYMS mRNA expression increase the toxic effect of 5-FU. Some polymorphisms in TYMS lead to modulation of TYMS mRNA expression, including a 3 0 UTR 6-bp deletion, a variable number of a 28-bp repeats (VNTR) in the promoter region (X3 instead of 2) and a G4C nucleotide change in the third repeat of the VNTR polymorphism. 1 Ishida et al. 2 reported a trend between the VNTR polymorphism of TYMS and the OS in GC patients with a nonsignificantly higher survival among patients carrying at least one allele with two 28-bp repeats (low expressing), compared to those with both alleles with three 28-bp repeats (high expressing). In subsequent studies, a combination of polymorphisms in the 5 0 UTR and 3 0 UTR of the TYMS gene was considered instead of the single 28-bp VNTR variant. Data from 187 GC patients indicate that a combination of the TYMS polymorphisms resulting in low-(two VNTR repeats, (C) in the third VNTR repeat, 3 0 UTR-6 bp-del) or high-(two VNTR repeats, (G) in the third VNTR repeat, 3 0 UTR-6 bp-ins) expressing alleles can discriminate between patients with different clinical outcomes. The patients presenting a combination of high-expressing alleles had a higher risk of relapse (P ¼ 0.003, by w 2 test), lower OS (hazard ratio (HR) ¼ 2.9, 95% confidence interval (CI): 1.7-4.1) and lower disease-free survival (DFS) (HR ¼ 3.5, 95% CI: 2.1-4.9). 3 A further study, considering the 3 0 UTR TYMS polymorphism in a population of 106 advanced GC patients, demonstrated a significantly higher response rate among patients with the 6-bp deletion in at least one allele (P ¼ 0.045). 4 The role of the TYMS polymorphisms on 5-FU sensitivity has been explored also for other tumors. In colorectal cancer (CRC) patients, the combination of 5 0 UTR and 3 0 UTR TYMS polymorphisms could discriminate between high and low responders in terms of improved DFS, with better survival in individuals carrying the low-expressing alleles. 5, 6 However, an opposite trend has been reported by Jakobsen et al. 7 Differences reported among studies could be due to several factors including genotyped tissues (healthy or tumor), which employed a different method of drug administration and a different treatment setting (metastatic disease vs adjuvant therapy). In any case, it is likely that a single polymorphism of TYMS is not sufficient to explain changes in the clinical benefit of 5-FU, and complex combinations of variants should be considered.
The DPYD polymorphism located in intron 14 of the DPYD gene (IV14 þ 1G4A) has been associated with reduced enzymatic activity. Patients carrying this polymorphism were more prone to develop G3-4 toxicity after 5-FU treatment. 8 However, the IV14 þ 1G4A is a quite rare polymorphism (variant allele o1%) and is therefore insufficient for explaining the severe 5-FU toxic effect expected in a more substantial percentage of patients. Nevertheless, the IV14 þ 1G4A allele has been associated with 5-FU toxic death in some studies 8 and thus should be included in the pharmacogenetic analysis of 5-FU.
Recently, the oral fluoropyrimidine capecitabine has been proposed for GC treatment. It is converted to 5-FU by thymidine phosphorylase. Although a number of mutations correlated with thymidine phosphorylase activity deficiency have been characterized, 9 no common polymorphisms with clear clinical meaning have been described for the encoding gene.
Impaired activity of methylenetetrahydrofolate reductase (MTHFR) increases intracellular levels of 5, 10-methylentetrahydrofolate, leading to an increased cytotoxic effect of 5-FU. Two common MTHFR polymorphisms, 677C4T and 1298G4A, have been associated with reduced MTHFR activity. Preliminary in vitro data supported a major role of the MTHFR 677C4T polymorphism in 5-FU cytotoxicity, 10 which was confirmed in clinical trials. Gao et al. 11 reported, in 75 advanced GC patients, a 6.57-fold (95% CI: 2.8-15.6) higher sensitivity to 5-FU among patients carrying a 677TT and a 1298AA genotypes compared to the others, demonstrating a strong predictive ability of these polymorphisms in response to 5-FU-based chemotherapy in GC. 11 Furthermore, in a population of 98 CRC patients, those carrying the variant T allele were more likely to respond to treatment (OR ¼ 1.88, 95% CI: 0.66-5.62). 12 More recently, Jakobsen et al. 7 reported a better prognosis for MTHFR 677TT patients (higher response rate, 66% for 677TT vs 33% for 677CT or 21% for 677CC, P ¼ 0.04) in a study of 88 CRC patients.
Methotrexate (MTX) is used in the FAMTX (5-FU, doxorubicin and MTX) regimen for treating GC. Pharmacogenetic implications of genes involved in folate metabolism, such as MTHFR, have been investigated extensively for MTX therapy. Many published studies concern the use of the drug in rheumatoid arthritis, where MTHFRÀ 677C4T and MTHFRÀ1298G4A polymorphisms appear to be associated with more severe toxicity of the treatment. MTHFR polymorphisms likely increase the toxicity and response to MTX by enhancing hyperhomocysteinemia subsequent to drug administration. 13, 14 Consistent with reports for rheumatoid arthritis, our group demonstrated in 43 ovarian cancer patients treated with MTX that the homozygous 677TT carriers had a greater risks of hyperhomocysteinemia and G3-4 toxicity. 15 In our study, as in the rheumatoid arthritis therapy, MTX was administered chronically for several days, and this could exacerbate the effect of deficiencies in folate metabolism. Nonetheless, the effect of MTHFR polymorphisms, when MTX was administered in pulse dose, as in the FAMTX regimen, remains to be elucidated further.
Other polymorphisms of genes involved in MTX transport (e.g., reduced folate carrier and the ATP-binding cassette C2) or of genes encoding MTX target proteins (e.g., dihydrofolate reductase, TYMS, AICARF and GAR transformylases) are under investigation, but only sparse, inconclusive data have been reported thus far. 16 Platinum derivatives, mainly cisplatin but more recently oxaliplatin, have been used in several chemotherapeutic regimens for treating GC. The pharmacogenetics of platinum derivatives is a topic of increased interest. In particular, genes that antagonize drug action, including those responsible for platinum detoxification (such as glutathione S-transferase (GST) genes) and DNA repair, have been investigated. Data on GST isoforms (in particular GSTT1, M1 and P1) involved in platinum derivative conjugation with glutathione seem to agree on a protective role against platinum-related toxicity and a detrimental role in chemotherapeutic response of highactivity GST alleles. The GSTP1 313G4A polymorphism results in reduced enzymatic activity and has been associated with improved survival and response after cisplatin/5-FU treatment in a population of 52 advanced GC patients. Patients with a 313AA genotype had a response rate of 67 vs 21% in patients with at least one 313G allele (P ¼ 0.038). Those patients also presented a significantly superior survival time (15 months vs 6) (P ¼ 0.037). 17 The same polymorphism has also been associated with more severe oxaliplatin-induced neuropathy in 299 CRC patients treated with 5-FU/ leucovorin/oxaliplatin (P ¼ 0.03).
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Polymorphisms of other GST isoforms, in particular the GSTM1, null genotype, characterized by a lack of enzymatic activity, have been linked to longer OS and progression-free interval in other neoplasms. 19 However, critical considerations must be made regarding the impact of GST polymorphisms on OS of patients treated with platinum derivatives for GC. Notably, GST polymorphisms might result in increased tumor response and better survival after platinum derivative chemotherapy, but at the same time they could be associated with increased risk of developing GC. 20 Among the DNA repair genes, the nucleotide excision repair system is considered to play a pivotal role in developing DNA repair-associated resistance to platinum therapy. Although no data for GC have been reported so far, different studies agreed on a detrimental role of the ERCC2 35931A4C (Lys751Gln) polymorphism in response and survival in some tumors. 21, 22 Recently, data have also emerged regarding ERCC1. In particular, the 8092C4A polymorphism has been associated with increased toxicity in non-small-cell lung cancer (NSCLC) patients treated with cisplatin/carboplatin-based therapy, 23 but data on the role of ERCC1 polymorphisms in response and survival need further clarification. [24] [25] [26] Regarding the base excision repair system, the XRCC1 28152G4A (Arg399Gln) polymorphism was linked to a shorter survival in patients affected by NSCLC 22 or CRC 27 and treated with platinum therapy. This XRCC1 polymorphism is located in the PARPbinding domain. 28 The PARP proteins exert complex regulatory and autoregulatory functions to transmit signals for DNA repair or apoptosis. Thus, a defect in this cellular pathway could lead to failure in apoptotic initiation in response to platinum-induced DNA damage. 29 
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Anthracyclines (doxorubicin or epirubicin) are used as single agents or in combination therapy for GC. Pharmacogenetics studies indicate a major effect of cellular transporters (ABCB1) and phase II metabolism enzymes (GSTT1, M1 and P1) on anthracycline pharmacology. The ABCB1 encoded protein mediates the cellular extrusion of platinum derivatives, whereas the GST family of enzymes detoxifies products of oxidative DNA damage, such as those generated by anthracyclines, through conjugation to glutathione. Data on GC, with regard to this topic, are still lacking; however, some studies on other neoplasms suggested a role of ABCB1À3435C4T polymorphism in improving the outcome of therapies with anthracyclines, 30, 31 whereas the GSTM1-and GSTT1-null genotypes seemed to improve the chance of disease recurrence and the OS. 32 Recently, data on 64 cases of locally advanced GC treated with a docetaxelcontaining regimen (docetaxel, 5-FU and carboplatin) indicated better OS (12.4 vs 8.7 months, P ¼ 0.0005) compared to a conventional ECF scheme (epirubicin, cisplatin and 5-FU). 33 Little data are available regarding genetic polymorphisms that influence docetaxel pharmacodynamics. CYP3A4 and CYP3A5 isoforms contribute to docetaxel oxidative metabolism, but a clinical trial on 31 docetaxel-treated solid cancer patients failed to correlate pharmacokinetic and pharmacodynamic profiles with CYP3A4*1B or CYP3A5*3 genotypes. 34 Among the topoisomerase I inhibitors, irinotecan (CPT11) is under investigation for treatment of GC. CPT11 is activated to SN38 by human carboxylesterases (CES1 and CES2). The pharmacogenetics of this drug has been investigated extensively, in CRC, especially concerning the uridinediphosphoglucuronosil transferase 1A1 (UGT1A1) polymorphism. UGT1A1 mediates the glucuronidation of SN38, thus inactivating it. The variant allele UGT1A1*28 is associated with reduced expression of the gene and was linked to higher plasmatic levels of SN38, a lower glucuronidation ratio (SN38 glucuronide/SN38) and severe neutropenia. 35, 36 However, this variant could also be associated with an increased response rate, so a dose reduction appears questionable in patients having the UGT1A1*28 polymorphism. 37 Carlini et al. 38 investigated polymorphisms in UGT1A7 and UGT1A9 genes, also involved in CPT11 glucuronidation, highlighting that they may be predictors of response and toxicity to CPT11 therapy. Mathijssen et al. 39 extended the analysis to polymorphisms of genes involved in metabolic and transport steps, such as ABCB1 and ABCC2 (CPT11 cell detoxification), CYP3A4 and CYP3A5 (CPT11 oxidative metabolism) and CES1 and CES2. A significant association with CPT11 pharmacokinetic parameters was found only for the ABCB1À1236C4T polymorphism, whereas no association was reported for UGT1A1*28. However, the authors noted the low prevalence of the UGT1A1*28 polymorphism in the Asian population used in the study. The correlation between CES2 polymorphisms and CPT11 toxicity and pharmacokinetics has not been fully explored. Nonetheless, recent studies evidenced a significant relationship between CES2 mRNA expression levels in lymphocytes and pharmacokinetics (P ¼ 0013), and a trend association of CES2 mRNA expression levels with drug toxicity, in 45 CRC patients treated with the FOLFIRI regimen. 40 These data encourage further studies on possible genetic markers of protein expression.
NADPH-quinone oxidoreductase (NQO1) catalyzes the reduction reaction activating mitomycin C, employed in some association schemes for GC treatment, to its cytotoxic semiquinone derivative. NQO1 polymorphism 609C4T has been associated with diminished catalytic efficacy of the enzyme and, in 117 gastrointestinal cancer patients, longer survival in wild-type genotype patients was reported (more than 43.6 vs 23 months, P ¼ 0.037). 41 The lack of an effective second-line chemotherapy in GC patients allows rapid regulatory approval of new active drugs, even at early stages of development. New target-oriented agents are under evaluation for treatment of GC, including tyrosine kinasetargeting drugs (epidermal growth factor receptor (EGFR) inhibitors such as cetuximab or gefitinib), anti-angiogenetic agents (anti-vascular endothelial growth factor (VEGF) antibodies such as bevacizumab), proteasome inhibitors (bortezomib) and anti-metastasis agents (matrix metalloproteinase inhibitors such as marimastat). 42 Pharmacogenetics is still an open field in targeted therapy. Moreover, considering that constitutive polymorphisms in genes such as EGFR or VEGF could be biased by the presence of extensive genetic aberrations, it is a challenge to identify polymorphisms strictly involved in tumor progression and to determine the impact of any single polymorphism. Typically, complex patterns of somatic mutations have been considered to predict clinical responses to these classes of drugs. 43 Nonetheless, some interesting data have emerged regarding a polymorphism present in intron 1 of EGFR. The number of repeats of a CA microsatellite (ranging from 9 to 21) influenced the expression level of the gene and was associated in vitro with response to EGFR tyrosine kinase inhibitors such as erlotinib. 44 Genetic polymorphisms with a functional impact on the protein have also been observed in other target genes such as VEGF, 45 but further studies are warranted.
In conclusion, current data on the pharmacogenetics of GC do not allow final conclusions, but some suggestions can be derived from studies investigating the impact of polymorphisms potentially affecting drugs used in GC on different pathologies. On these grounds, toxicity data, derived from any area of oncology, are likely to be relevant also to GC patients. Conversely, concerning efficacy, data from other tumors could only give suggestions of the real effect of genetic polymorphisms on GC sensitivity to chemotherapy. Nonetheless, emerging data, recently produced on GC patients, especially about the impact of genetic polymorphisms on sensitivity to 5-FU and platinum derivatives, seemed to agree with those produced, for the same drugs, on different pathologies. This encourages to take into account also the pharmacogenetic data derived from different tumors, if produced for drugs commonly employed in GC, as they could be translatable also on GC.
In recent years, it has become clear that a pharmacogenetic approach represents a potential tool for optimizing treatments for several human tumors, and it is imperative to expand existing knowledge about the pharmacogenetics of GC. Moreover, some pharmacogenetic determinants are not involved in the metabolism or transport of anti-neoplastic drugs, but in xenobiotics, and these can contribute to the development of GC.
For translating pharmacogenetics to GC therapy, topics such as the methodological criteria for pharmacogenetic trials must be better defined, with more appropriate study design. A more accurate definition of genotype-phenotype correlation is still needed. Finally, GC patients are treated with poly-chemotherapeutic regimens in association with non-antineoplastic drugs, and the influence of pharmacogenetic determinants on drug-drug interactions needs to be elucidated.
Metabolism and clearance of antineoplastic drugs may be complex, requiring contributions from multiple genes. Therefore, multiple gene or haplotype analyses are required. It is thus important to define a hierarchy of polymorphisms to be considered for a specific combination treatment to aid the clinician in choosing the appropriate drug and dosage. Finally, low-cost genotype screening will be necessary, as the ultimate goal is predicting an individual response to a given drug or drug combination based on the genetic make-up of the patient. 
